FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. <i>See</i>	STATEMENT OF CHANGES IN
Instruction 1(b).	Filed pursuant to Section 16(a) of the

BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

1. Name and Address of Reporting Person* D'Onofrio Matthew J						2. Issuer Name and Ticker or Trading Symbol Evoke Pharma Inc [EVOK]								Chec	k all applic	cable)	g Pers	on(s) to Issi 10% Ow Other (s	ner
(Last) (First) (Middle) C/O EVOKE PHARMA, INC. 505 LOMAS SANTA FE DRIVE, SUITE 270					3. Date of Earliest Transaction (Month/Day/Year) 12/02/2013								X	below)		ef Bu	below)	r3",	
(Street) SOLANA BEACH (City)			92075 (Zip)		4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)							3. Ind Line)						
,	`		ole I - Non-	-Deriva	ative	e Se	curities	s Ac	quired,	Dis	posed o	of, or Be	nefici	ally	Owned				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date,			Code (Instr. 5)			str. 3, 4 a		5. Amount of Securities Beneficially Owned Following Reported		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	nt (A) or Pr		:е	Transact (Instr. 3 a					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/	ate, Ti	Code (In				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		1	Derivative Security Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				c	Code	v	(A)	(D)	Date Exercisabl		Expiration Date	Title	Amou or Numb of Share	er					
Stock Option (Right to Buy)	\$8.67	12/02/2013			A		94,250		(1)	1	2/01/2023	Common Stock	94,25	50	\$0.00	94,250		D	

Explanation of Responses:

1. The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period following the date of grant (12/2/2013), subject to the reporting person's continued service to the Issuer through each such vesting date.

Remarks:

/s/ Matthew J. D'Onofrio

12/03/2013

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.